Baergic Bio, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of CNS disorders. Baergic Bio’s lead asset, BAER-101, is a novel α2/3–subtype-selective GABA A positive allosteric modulator currently being explored in both a clinical and pre-clinical setting in areas of unmet need. Baergic Bio is located in New York City and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO).

DECEMBER 23, 2019: FORTRESS BIOTECH ANNOUNCES EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH ASTRAZENECA AND CINCINNATI CHILDREN’S HOSPITAL MEDICAL CENTER TO DEVELOP A NOVEL TREATMENT FOR SELECT CNS DISORDERS



"We are in hibernation. Website coming soon!"

2 Gansevoort Street, 9th Floor
New York, NY 10014